About this module
Dr Richard Russell and Prof Christian Taube discuss the new insights on the pathophysiology of COPD. COPD is often depicted as an inflammatory disease, but experimental data presented at ATS 2016 shows that non-inflammatory mechanisms have a role in the development of the disease.
Several studies presented at ATS 2016 showed that elastin degradation is elevated in patients with COPD. Therefore, elastin may represent an important marker for preventative strategies in COPD.
An emerging area of interest in COPD is the lung microbiome and the interaction of our immune system with microbes. Fascinating data presented at the congress showed that there is a loss of diversity in the microbiome at the time of exacerbation. Interestingly, antibiotics do not sterilise the lung but rather change the balance of the microbiome. Understanding these mechanisms may change prognosis for our patients.
This webinar episode is part of the ATS 2016 webinar series outlined below.
- Introduction to the ATS 2016 webinar series for COPD
- Asthma-COPD overlap syndrome (ACOS)
- Phenotypes, traits and clusters in COPD
- Eosinophils and other biomarkers for COPD
- Combination therapy in COPD: recent data from clinical trials
- ICS use in COPD
- Exacerbations in COPD
- Co-morbidities of COPD
- Structural mechanisms of COPD and the lung microbiome
- Biomass fuels and their role in COPD
- Smoking cessation and e-Cigarettes
- Pulmonary rehabilitation for COPD
- Diagnosis and spirometry in COPD
- 3 mins
- Monday, August 1, 2016
- Dr Richard Russell and Prof Christian Taube
- Developments in Respiratory